Selected research
Industry Research
Osimertinib Industry Research Report 2026
Market perspective
The global Osimertinib market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Osimertinib is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Osimertinib is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Osimertinib is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Osimertinib include Beacon Pharma, Drug International, Everest Pharmaceuticals, Incepta Pharmaceuticals Limited and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Osimertinib market in terms of revenue (US$ million) and, where applicable, sales volume (k pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k pcs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Osimertinib Market by Company
Beacon Pharma
Drug International
Everest Pharmaceuticals
Incepta Pharmaceuticals Limited
AstraZeneca
Osimertinib Segment by Type
80mg*30 Tablets
80mg*10 Tablets
40mg*30 Tablets
40mg*10 Tablets
Osimertinib Segment by Application
Locally Advanced NSCLC
Metastatic NSCLC
Others
Osimertinib Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Osimertinib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Osimertinib and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Osimertinib.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Osimertinib manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Osimertinib by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Osimertinib in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 80mg*30 Tablets
- 80mg*10 Tablets
- 40mg*30 Tablets
- 40mg*10 Tablets
Applications
- Locally Advanced NSCLC
- Metastatic NSCLC
- Others
Companies covered
- Beacon Pharma
- Drug International
- Everest Pharmaceuticals
- Incepta Pharmaceuticals Limited
- AstraZeneca
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Osimertinib Market Size (2021-2032)
- 2.2.2 Global Osimertinib Sales (2021-2032)
- 2.2.3 Global Osimertinib Market Average Price (2021-2032)
- 2.3 Osimertinib by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 80mg*30 Tablets
- 2.3.3 80mg*10 Tablets
- 2.3.4 40mg*30 Tablets
- 2.3.5 40mg*10 Tablets
- 2.4 Osimertinib by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Locally Advanced NSCLC
- 2.4.3 Metastatic NSCLC
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Osimertinib Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Osimertinib Sales (k pcs) of Manufacturers (2021-2026)
- 3.3 Global Osimertinib Revenue of Manufacturers (2021-2026)
- 3.4 Global Osimertinib Average Price by Manufacturers (2021-2026)
- 3.5 Global Osimertinib Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Osimertinib, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Osimertinib, Product Type & Application
- 3.8 Global Manufacturers of Osimertinib, Established Date
- 3.9 Global Osimertinib Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Beacon Pharma
- 4.1.1 Beacon Pharma Company Information
- 4.1.2 Beacon Pharma Business Overview
- 4.1.3 Beacon Pharma Osimertinib Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Beacon Pharma Osimertinib Product Portfolio
- 4.1.5 Beacon Pharma Recent Developments
- 4.2 Drug International
- 4.2.1 Drug International Company Information
- 4.2.2 Drug International Business Overview
- 4.2.3 Drug International Osimertinib Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Drug International Osimertinib Product Portfolio
- 4.2.5 Drug International Recent Developments
- 4.3 Everest Pharmaceuticals
- 4.3.1 Everest Pharmaceuticals Company Information
- 4.3.2 Everest Pharmaceuticals Business Overview
- 4.3.3 Everest Pharmaceuticals Osimertinib Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Everest Pharmaceuticals Osimertinib Product Portfolio
- 4.3.5 Everest Pharmaceuticals Recent Developments
- 4.4 Incepta Pharmaceuticals Limited
- 4.4.1 Incepta Pharmaceuticals Limited Company Information
- 4.4.2 Incepta Pharmaceuticals Limited Business Overview
- 4.4.3 Incepta Pharmaceuticals Limited Osimertinib Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Incepta Pharmaceuticals Limited Osimertinib Product Portfolio
- 4.4.5 Incepta Pharmaceuticals Limited Recent Developments
- 4.5 AstraZeneca
- 4.5.1 AstraZeneca Company Information
- 4.5.2 AstraZeneca Business Overview
- 4.5.3 AstraZeneca Osimertinib Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 AstraZeneca Osimertinib Product Portfolio
- 4.5.5 AstraZeneca Recent Developments
5 Global Osimertinib Market Scenario by Region
- 5.1 Global Osimertinib Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Osimertinib Sales by Region: 2021-2032
- 5.2.1 Global Osimertinib Sales by Region: 2021-2026
- 5.2.2 Global Osimertinib Sales by Region: 2027-2032
- 5.3 Global Osimertinib Revenue by Region: 2021-2032
- 5.3.1 Global Osimertinib Revenue by Region: 2021-2026
- 5.3.2 Global Osimertinib Revenue by Region: 2027-2032
- 5.4 North America Osimertinib Market Facts & Figures by Country
- 5.4.1 North America Osimertinib Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Osimertinib Sales by Country (2021-2032)
- 5.4.3 North America Osimertinib Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Osimertinib Market Facts & Figures by Country
- 5.5.1 Europe Osimertinib Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Osimertinib Sales by Country (2021-2032)
- 5.5.3 Europe Osimertinib Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Osimertinib Market Facts & Figures by Country
- 5.6.1 Asia Pacific Osimertinib Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Osimertinib Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Osimertinib Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Osimertinib Market Facts & Figures by Country
- 5.7.1 South America Osimertinib Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Osimertinib Sales by Country (2021-2032)
- 5.7.3 South America Osimertinib Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Osimertinib Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Osimertinib Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Osimertinib Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Osimertinib Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Osimertinib Sales by Type (2021-2032)
- 6.1.1 Global Osimertinib Sales by Type (2021-2032) & (k pcs)
- 6.1.2 Global Osimertinib Sales Market Share by Type (2021-2032)
- 6.2 Global Osimertinib Revenue by Type (2021-2032)
- 6.2.1 Global Osimertinib Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Osimertinib Revenue Market Share by Type (2021-2032)
- 6.3 Global Osimertinib Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Osimertinib Sales by Application (2021-2032)
- 7.1.1 Global Osimertinib Sales by Application (2021-2032) & (k pcs)
- 7.1.2 Global Osimertinib Sales Market Share by Application (2021-2032)
- 7.2 Global Osimertinib Revenue by Application (2021-2032)
- 7.2.1 Global Osimertinib Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Osimertinib Revenue Market Share by Application (2021-2032)
- 7.3 Global Osimertinib Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Osimertinib Value Chain Analysis
- 8.1.1 Osimertinib Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Osimertinib Production Mode & Process
- 8.2 Osimertinib Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Osimertinib Distributors
- 8.2.3 Osimertinib Customers
9 Global Osimertinib Analyzing Market Dynamics
- 9.1 Osimertinib Industry Trends
- 9.2 Osimertinib Industry Drivers
- 9.3 Osimertinib Industry Opportunities and Challenges
- 9.4 Osimertinib Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst